iRadimed (NASDAQ:IRMD) Hits New 1-Year High – Here’s Why

iRadimed Corporation (NASDAQ:IRMD) shares reached a new 52-week high on Tuesday . The stock traded as high as $103.11 and last traded at $102.7660, with a volume of 38362 shares. The stock had previously closed at $102.00.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on IRMD. Wall Street Zen lowered shares of iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Roth Capital set a $90.00 price objective on iRadimed in a research note on Friday, October 31st. Lake Street Capital reaffirmed a “buy” rating and set a $100.00 target price on shares of iRadimed in a research note on Monday, November 3rd. Zacks Research upgraded iRadimed to a “hold” rating in a report on Tuesday, November 4th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $87.33.

iRadimed Trading Up 1.0%

The stock’s 50-day moving average price is $94.73 and its 200-day moving average price is $78.78. The company has a market cap of $1.31 billion, a P/E ratio of 62.41 and a beta of 1.09.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Monday, November 3rd. The medical equipment provider reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.04. The business had revenue of $21.20 million during the quarter, compared to analyst estimates of $20.50 million. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.iRadimed has set its Q4 2025 guidance at 0.470-0.510 EPS and its FY 2025 guidance at 1.840-1.880 EPS. On average, research analysts anticipate that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The company also recently announced a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were issued a $0.50 dividend. The ex-dividend date was Wednesday, December 17th. iRadimed’s dividend payout ratio (DPR) is currently 41.21%.

Insider Buying and Selling at iRadimed

In other news, CFO John Glenn sold 15,000 shares of iRadimed stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the completion of the transaction, the chief financial officer directly owned 7,362 shares in the company, valued at $716,248.98. This trade represents a 67.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Roger E. Susi sold 5,000 shares of the business’s stock in a transaction dated Monday, January 12th. The stock was sold at an average price of $97.45, for a total transaction of $487,250.00. Following the sale, the chief executive officer directly owned 2,272,500 shares of the company’s stock, valued at approximately $221,455,125. The trade was a 0.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 55,000 shares of company stock valued at $5,077,100. 36.80% of the stock is currently owned by insiders.

Hedge Funds Weigh In On iRadimed

A number of hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC lifted its holdings in iRadimed by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock worth $6,848,000 after acquiring an additional 33,072 shares during the period. Johnson Investment Counsel Inc. bought a new position in iRadimed in the 2nd quarter valued at $1,534,000. Algert Global LLC increased its position in shares of iRadimed by 87.5% during the 3rd quarter. Algert Global LLC now owns 50,797 shares of the medical equipment provider’s stock valued at $3,615,000 after purchasing an additional 23,710 shares during the last quarter. UBS Group AG raised its stake in shares of iRadimed by 389.9% during the 3rd quarter. UBS Group AG now owns 25,433 shares of the medical equipment provider’s stock worth $1,810,000 after purchasing an additional 20,242 shares during the period. Finally, Punch & Associates Investment Management Inc. purchased a new position in shares of iRadimed in the 3rd quarter worth about $1,210,000. Institutional investors and hedge funds own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.